Transatlantique Private Wealth LLC Trims Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Transatlantique Private Wealth LLC cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 37.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,207 shares of the medical instruments supplier’s stock after selling 2,535 shares during the period. Transatlantique Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $971,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company during the 4th quarter worth $27,000. OLD Point Trust & Financial Services N A acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at about $29,000. Scarborough Advisors LLC purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at approximately $32,000. Rise Advisors LLC acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth approximately $38,000. Finally, ICA Group Wealth Management LLC purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $42,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on BDX. Citigroup cut their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Evercore ISI dropped their price target on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. The Goldman Sachs Group started coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price objective for the company. Finally, Raymond James dropped their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $233.50 on Friday. The stock has a fifty day moving average price of $235.51 and a 200 day moving average price of $235.52. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The stock has a market cap of $67.48 billion, a PE ratio of 51.43, a P/E/G ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.96 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.